3Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human cancer xenografts[J]. Clin Cancer Res, 1998,4: 1013-1019.
9Mundy GR, Yoneda T, Hiraga T. Preellnical studies with zoledronie acid and other bisphosphonares : impct on the bone mieroenvironment [J]. Semin Oncol, 2001,28(4) : 35-44.
10Rosen LS, Gordon D, Tchek Medyian S, et al. Long Term efficacy and safety of Zoledronicacid compared with pamidronate disodium in the treatment of skeletal complication in patients with advanced multi- ple or breast carcinoma: flrandomized, double-blind, multlcenter, comparative trial[J]. Cancer, 2003,98(8) : 1735-1744.
3[1]Wiser W,Berger A.Practical management of chemotherapy-induced nausea and vomiting.Oncology Williston Park),2005,19:637
4[2]Aapro M,et al.Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients recieving highly emetogenic chemotherapy (HEC)[Abstract].Support Care Cancer,2003,11:A17
5[3]Jordan K,Kasper C,Schmoll HJ.Chemotherapy-induced nausea and vomiting:Current and new standards in the antiemetic prophylaxis and treatment.Eur J Cancer,2005,41:199
6[4]Roila F,Donati D,Tamberi S,et al.Delayed emesis:Incidence,pattern,prognostic factors and optimal treatment.Support Care Cancer,2002,10:88
7[5]website:http//www.mascc.org.Multinational association for supportive care in cancer.Consensus Conference on antiemitic therapy Perugia,2004,March 29-31
8[6]Hesketh PJ,Kris MG,Grunberg SM,et al.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol,1997,15:103
9[7]Morrow GR.The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy.Cancer,1985,55:2766
10[8]Osoba D,Zee B,Pater J,et al.Determinants of postchemotherapy nausea and vomiting in patients with cancer.Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,1997,15:116
3Heffner JE.Management of the patient with amalignant pleural effu-sion [ J].Semin Respir Crit Care Med,2010,31(6):723-733.
4Lynch TJ,Bell DW,Sordell AR,et al.Activating mutations in the epidermal growth factor receptor underlying responsivetle of nonsmall-cell lung cancer to gefitinib [ J ].N Engl J Med,2004,350(21):2129-2139.
5So WK, Marsh G, Ling WM, et al. The symptom cluster of fa- tigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multi- center study[J]. Oncol Nurs Forum, 2009,36(4) :E205-214.
6Bergamaschi A, Madak-EMogan Z, Kim Y, et al. The forkhead tin- scription factor FOXM1 promotes endocrine resistance and invasive- ness in estrogen receptor-positive breast cancer by expansion of stem- like cancer cells[J]. Breast Cancer Res, 2014,16(5) :436.
7Pelicano H, Zhang W, Liu J, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of roTOR path- way and therapeutic potential [ J ]. Breast Cancer Res, 2014, 16(5) :434.
8Miura D, Yoneymna K, Furuhata Y, et al. Paelitaxel enhances zaati- body-dependent cell-medialed eytotoxieity of trastuzumab by rapid re- cruitment of natural killer cells in HER2-positive breast earteer[J]. J Nippon Med Seh, 2014,81 (4) :211-220.
9Bjrneklett HG, Lindemalm C, Rosenblad A, et al. A randomised controlled trial of support group intervention after breast cancer treatment., results on inxiety and depression [ J ]. Acta Oncol, 2012,51 (2) :198-207.
10Ahem TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities[ J]. Lancet Oncol, 2014, 15(10) :e461 468.
